Topics:
Hematologic Malignancies • Pediatric Oncology • Medical Oncology • Lymphoma • NCI-CCC Tumor Board Question • Hematology • NCI-CCC Lymphoma Tumor Board Question • City of Hope
What is the preferred treatment for a patient with an EBV+ monomorphic PTLD (DLBCL) not currently on immunosuppressive therapy?
Answer from: Medical Oncologist at Academic Institution
For patients who are candidates for an anthracycline-based regimen, R-CHOP is usually given if CD20+ PTLD. Patients whose tumors do not express CD20 are treated with CHOP chemotherapy alone. R-CHOP can lead to ~ 65% of CR (Trappe et al., PMID 22173060).
Sign in or Register to read more